Hohl Benjamin (CIK 1882764) reported 41 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-08-19). Recent activity: Sell ELVN (4,630 shares), Sell ELVN (1,388 shares), Buy ELVN (1,072 shares), Sell ELVN (324 shares), Sell ELVN (369 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 4,630 | $270,168 |
| 2026-08-19 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 1,388 | $82,383 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 1,072 | $2,659 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 324 | $16,191 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 369 | $18,997 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 2,564 | $134,143 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 2,638 | $140,823 |
| 2026-07-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 123 | $6,626 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 6,018 | $14,925 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 1,379 | $59,001 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,401 | $149,179 |
| 2026-06-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 1,238 | $55,397 |
| 2026-03-10 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 10,000 | $295,800 |
| 2026-02-17 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 25,000 | $0 |
| 2025-12-23 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 13,000 | $32,240 |
| 2025-10-01 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,250 | $8,060 |
| 2025-10-01 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $66,300 |
| 2025-08-29 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,250 | $8,060 |
| 2025-08-29 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,250 | $67,048 |
| 2025-07-30 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,250 | $8,060 |
| 2025-07-30 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 3,185 | $65,133 |
| 2025-07-30 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 65 | $1,384 |
| 2025-07-14 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 1,000 | $2,480 |
| 2025-07-14 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Sell | 1,000 | $22,660 |
| 2025-07-01 | Enliven Therapeutics, Inc. (ELVN) | CHIEF FINANCIAL OFFICER | Buy | 3,250 | $8,060 |
Source: SEC Form 4 filings · as of 2026-08-19